As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority.
Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives.
As people live longer, chronic conditions are on the rise. New viruses and diseases are emerging, while old enemies like cancer and neurodegenerative diseases remain. Sanofi is driven by the scope of these health challenges.
As of 30 June 2021, the drugs and vaccines in Sanofi's R&D pipeline include 83 projects, 35 of which are in phase 3 or have been submitted to regulatory authorities for approval. These projects represent new molecular entities as well as existing therapeutics being investigated for additional indications, or different formulations.
Sanofi is investing in these research areas to find innovative solutions for patients:
In recent years, Sanofi has led the science in immunology by introducing new treatment options for chronic, difficult-to-treat inflammatory diseases such as atopic dermatitis (eczema), asthma and rheumatoid arthritis. Sanofi is applying the most advanced research technologies and is focused on inflammatory conditions and autoimmune diseases with the highest unmet need. One of its key approaches is to develop multi-specific antibody therapies that combine multiple mechanisms of action in a single molecule and that target two or more molecular pathways simultaneously.
Sanofi has a strong foundation in lysosomal storage disorders: a group of rare, genetic conditions caused by enzyme deficiencies. Its teams are developing pioneering medicines for disorders such as Fabry, Gaucher, and Pompe diseases, and advancing toward new treatments for patients with GM2 gangliosidoses (Tay-Sachs disease, AB variant, and Sandhoff disease) and acid sphingomyelinase deficiency (ASMD). The insights gained from research into rare diseases can have applications for other diseases, for example leading to clinical studies of autosomal dominant polycystic kidney disease (ADPKD) and Alport syndrome.
Sanofi Pasteur is at the forefront of vaccine research and development, creating immunological solutions to prevent and cure diseases for every stage of life. It continuously harnesses new scientific knowledge and technologies to design safe and effective vaccines against complex diseases. Innovation is key to improving people's health around the world and also to the company's success. That is why it devotes more than €1 million to research and development every day. Sanofi Pasteur works every day to turn scientific breakthroughs and personal health insights into protective vaccines for people around the world.
Next Generation Approaches to Pioneer Breakthrough Therapies
At Sanofi, we are developing medicines that have the potential to help transform patients’ lives by using the most advanced technology platforms to pioneer new innovative approaches to tackle diseases.